Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under
highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3, but its
activity in patients without antiretroviral therapy is unknown. This study will test the
efficacy and safety of IL-2 in naïve patients with a CD4 count between 300 and 500/m3.
Phase:
Phase 2
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis